Orphazyme AS (CHIX:ORPHAC) Receivables Turnover : 0.00 (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Orphazyme AS's Revenue for the three months ended in Jun. 2022 was kr0.00 Mil. Orphazyme AS's average Accounts Receivable for the three months ended in Jun. 2022 was kr26.52 Mil.

Orphazyme AS Receivables Turnover Historical Data

The historical data trend for Orphazyme AS's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Receivables Turnover Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Receivables Turnover

Get a 7-Day Free Trial

1.24

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Receivables Turnover	Get a 7-Day Free Trial									-	-	-	1.30	-

Competitive Comparison of Orphazyme AS's Receivables Turnover

For the Biotechnology subindustry, Orphazyme AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orphazyme AS's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Receivables Turnover falls into.

Orphazyme AS Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Orphazyme AS's Receivables Turnover for the fiscal year that ended in Dec. 2021 is calculated as

	Receivables Turnover (A: Dec. 2021 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2021 )	/ (	(Accounts Receivable (A: Dec. 2020 )	+	Accounts Receivable (A: Dec. 2021 ))	/	count )
=	36.193	/ (	(0	+	29.268)	/	1 )
=	36.193	/	29.268
=	1.24

Orphazyme AS's Receivables Turnover for the quarter that ended in Jun. 2022 is calculated as

	Receivables Turnover (Q: Jun. 2022 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2022 )	/ (	(Accounts Receivable (Q: Dec. 2021 )	+	Accounts Receivable (Q: Jun. 2022 ))	/	count )
=	0	/ (	(29.268	+	23.765)	/	2 )
=	0	/	26.5165
=	N/A

Orphazyme AS (CHIX:ORPHAc) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Orphazyme AS Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines